GenSight Biologics sets Sept. 29 release for H1 2026 financial statement

Reuters2026/09/08 05:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

GenSight Biologics reported the GS010/LUMEVOQ manufacturing transfer to Catalent stayed on track, with viral genome titer within target specifications.
Upstream transfer testing for the drug substance is expected by end-summer, with GMP batch manufacturing preparations already initiated.
All remaining patients for the REVISE dose-ranging study in France have been identified; last treatment is scheduled for December 2026.
Named-patient early access screening in France resumed, with some patients treated; first named-patient early access treatment in Israel occurred in July.
Half-year 2026 financial statement is scheduled for release after market close on Sept. 29, 2026; quiet period begins Sept. 15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609080130BIZWIRE_USPR_____20260907_BW527861) on September 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

GenSight Biologics sets Sept. 29 release for H1 2026 financial statement

You may also like

Crypto prices